ID   PAK1_HUMAN              Reviewed;         545 AA.
AC   Q13153; O75561; Q13567; Q32M53; Q32M54; Q86W79;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   12-OCT-2022, entry version 234.
DE   RecName: Full=Serine/threonine-protein kinase PAK 1 {ECO:0000303|PubMed:8805275};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:22153498, ECO:0000269|PubMed:9032240};
DE   AltName: Full=Alpha-PAK {ECO:0000303|PubMed:9528787};
DE   AltName: Full=p21-activated kinase 1 {ECO:0000303|PubMed:9395435};
DE            Short=PAK-1;
DE   AltName: Full=p65-PAK {ECO:0000250|UniProtKB:P35465};
GN   Name=PAK1 {ECO:0000312|HGNC:HGNC:8590};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=8805275; DOI=10.1016/s0960-9822(02)00546-8;
RA   Brown J.L., Stowers L., Baer M., Trejo J., Coughlin S., Chant J.;
RT   "Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway.";
RL   Curr. Biol. 6:598-605(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=9395435; DOI=10.1016/s0960-9822(97)70091-5;
RA   Sells M.A., Knaus U.G., Bagrodia S., Ambrose D.M., Bokoch G.M.,
RA   Chernoff J.;
RT   "Human p21-activated kinase (Pak1) regulates actin organization in
RT   mammalian cells.";
RL   Curr. Biol. 7:202-210(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Reid T., Aspenstroem P., Bertoglio J.;
RT   "Human PAK1B.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, ACTIVITY REGULATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9032240; DOI=10.1128/mcb.17.3.1129;
RA   Manser E., Huang H.Y., Loo T.H., Chen X.Q., Dong J.M., Leung T., Lim L.;
RT   "Expression of constitutively active alpha-PAK reveals effects of the
RT   kinase on actin and focal complexes.";
RL   Mol. Cell. Biol. 17:1129-1143(1997).
RN   [7]
RP   MUTAGENESIS OF HIS-83 AND HIS-86.
RX   PubMed=9774440; DOI=10.1074/jbc.273.43.28191;
RA   Frost J.A., Khokhlatchev A., Stippec S., White M.A., Cobb M.H.;
RT   "Differential effects of PAK1-activating mutations reveal activity-
RT   dependent and -independent effects on cytoskeletal regulation.";
RL   J. Biol. Chem. 273:28191-28198(1998).
RN   [8]
RP   FUNCTION, AND AUTOREGULATORY DOMAIN.
RX   PubMed=9528787; DOI=10.1128/mcb.18.4.2153;
RA   Zhao Z.S., Manser E., Chen X.Q., Chong C., Leung T., Lim L.;
RT   "A conserved negative regulatory region in alphaPAK: inhibition of PAK
RT   kinases reveals their morphological roles downstream of Cdc42 and Rac1.";
RL   Mol. Cell. Biol. 18:2153-2163(1998).
RN   [9]
RP   INTERACTION WITH NCK1 AND NCK2.
RX   PubMed=10026169; DOI=10.1074/jbc.274.9.5542;
RA   Braverman L.E., Quilliam L.A.;
RT   "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing
RT   adapter protein having similar binding and biological properties to Nck.";
RL   J. Biol. Chem. 274:5542-5549(1999).
RN   [10]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AUTOREGULATORY REGION, FUNCTION,
RP   INTERACTION WITH CDC42, PHOSPHORYLATION AT THR-423, AND MUTAGENESIS OF
RP   HIS-83; HIS-86; LEU-107 AND THR-423.
RX   PubMed=10551809; DOI=10.1074/jbc.274.46.32565;
RA   Zenke F.T., King C.C., Bohl B.P., Bokoch G.M.;
RT   "Identification of a central phosphorylation site in p21-activated kinase
RT   regulating autoinhibition and kinase activity.";
RL   J. Biol. Chem. 274:32565-32573(1999).
RN   [11]
RP   PHOSPHORYLATION AT THR-423 BY PDPK1, INTERACTION WITH PDPK1, AND ACTIVITY
RP   REGULATION.
RX   PubMed=10995762; DOI=10.1074/jbc.m006553200;
RA   King C.C., Gardiner E.M., Zenke F.T., Bohl B.P., Newton A.C.,
RA   Hemmings B.A., Bokoch G.M.;
RT   "p21-activated kinase (PAK1) is phosphorylated and activated by 3-
RT   phosphoinositide-dependent kinase-1 (PDK1).";
RL   J. Biol. Chem. 275:41201-41209(2000).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1.
RX   PubMed=11733498; DOI=10.1074/jbc.m110000200;
RA   Zang M., Hayne C., Luo Z.;
RT   "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation
RT   and activation of Raf-1.";
RL   J. Biol. Chem. 277:4395-4405(2002).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11896197; DOI=10.1242/jcs.115.7.1497;
RA   Manabe R., Kovalenko M., Webb D.J., Horwitz A.R.;
RT   "GIT1 functions in a motile, multi-molecular signaling complex that
RT   regulates protrusive activity and cell migration.";
RL   J. Cell Sci. 115:1497-1510(2002).
RN   [14]
RP   SUBUNIT, AND ACTIVITY REGULATION.
RX   PubMed=11804587; DOI=10.1016/s1097-2765(01)00428-2;
RA   Parrini M.C., Lei M., Harrison S.C., Mayer B.J.;
RT   "Pak1 kinase homodimers are autoinhibited in trans and dissociated upon
RT   activation by Cdc42 and Rac1.";
RL   Mol. Cell 9:73-83(2002).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH CDC2L1 AND CDC2L2.
RX   PubMed=12624090; DOI=10.1074/jbc.m300818200;
RA   Chen S., Yin X., Zhu X., Yan J., Ji S., Chen C., Cai M., Zhang S., Zong H.,
RA   Hu Y., Yuan Z., Shen Z., Gu J.;
RT   "The C-terminal kinase domain of the p34cdc2-related PITSLRE protein kinase
RT   (p110C) associates with p21-activated kinase 1 and inhibits its activity
RT   during anoikis.";
RL   J. Biol. Chem. 278:20029-20036(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=12876277; DOI=10.1083/jcb.200212141;
RA   Slack-Davis J.K., Eblen S.T., Zecevic M., Boerner S.A., Tarcsafalvi A.,
RA   Diaz H.B., Marshall M.S., Weber M.J., Parsons J.T., Catling A.D.;
RT   "PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK
RT   activation.";
RL   J. Cell Biol. 162:281-291(2003).
RN   [17]
RP   PHOSPHORYLATION AT SER-21, IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION,
RP   INTERACTION WITH NCK1, AND SUBCELLULAR LOCATION.
RX   PubMed=14585966; DOI=10.1128/mcb.23.22.8058-8069.2003;
RA   Zhou G.L., Zhuo Y., King C.C., Fryer B.H., Bokoch G.M., Field J.;
RT   "Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell
RT   migration.";
RL   Mol. Cell. Biol. 23:8058-8069(2003).
RN   [18]
RP   RETRACTED PAPER.
RX   PubMed=15169762; DOI=10.1074/jbc.m401878200;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 279:32824-32831(2004).
RN   [19]
RP   RETRACTION NOTICE OF PUBMED:15169762.
RX   PubMed=26048998; DOI=10.1074/jbc.a115.401878;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 290:14797-14797(2015).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=15833848; DOI=10.1158/0008-5472.can-04-3480;
RA   Yang Z., Rayala S., Nguyen D., Vadlamudi R.K., Chen S., Kumar R.;
RT   "Pak1 phosphorylation of snail, a master regulator of epithelial-to-
RT   mesenchyme transition, modulates snail's subcellular localization and
RT   functions.";
RL   Cancer Res. 65:3179-3184(2005).
RN   [21]
RP   FUNCTION.
RX   PubMed=15611088; DOI=10.1074/jbc.m411900200;
RA   Zhou H., Kramer R.H.;
RT   "Integrin engagement differentially modulates epithelial cell motility by
RT   RhoA/ROCK and PAK1.";
RL   J. Biol. Chem. 280:10624-10635(2005).
RN   [22]
RP   INTERACTION WITH CIB1, AND SUBCELLULAR LOCATION.
RX   PubMed=16061695; DOI=10.1083/jcb.200502090;
RA   Leisner T.M., Liu M., Jaffer Z.M., Chernoff J., Parise L.V.;
RT   "Essential role of CIB1 in regulating PAK1 activation and cell migration.";
RL   J. Cell Biol. 170:465-476(2005).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH TBCB.
RX   PubMed=15831477; DOI=10.1128/mcb.25.9.3726-3736.2005;
RA   Vadlamudi R.K., Barnes C.J., Rayala S., Li F., Balasenthil S., Marcus S.,
RA   Goodson H.V., Sahin A.A., Kumar R.;
RT   "p21-activated kinase 1 regulates microtubule dynamics by phosphorylating
RT   tubulin cofactor B.";
RL   Mol. Cell. Biol. 25:3726-3736(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-212, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [25]
RP   CAUTION.
RX   PubMed=16278681; DOI=10.1038/sj.onc.1209172;
RA   Talukder A.H., Meng Q., Kumar R.;
RT   "CRIPak, a novel endogenous Pak1 inhibitor.";
RL   Oncogene 25:1311-1319(2006).
RN   [26]
RP   FUNCTION, PHOSPHORYLATION AT TYR-153; TYR-201 AND TYR-285, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17726028; DOI=10.1074/jbc.m701794200;
RA   Rider L., Shatrova A., Feener E.P., Webb L., Diakonova M.;
RT   "JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and
RT   functions.";
RL   J. Biol. Chem. 282:30985-30996(2007).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT SER-21; SER-57; TYR-131; TYR-142; TYR-153;
RP   SER-174; THR-185; THR-212 AND TYR-285, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=17989089; DOI=10.1242/jcs.008177;
RA   Mayhew M.W., Jeffery E.D., Sherman N.E., Nelson K., Polefrone J.M.,
RA   Pratt S.J., Shabanowitz J., Parsons J.T., Fox J.W., Hunt D.F.,
RA   Horwitz A.F.;
RT   "Identification of phosphorylation sites in betaPIX and PAK1.";
RL   J. Cell Sci. 120:3911-3918(2007).
RN   [28]
RP   INTERACTION WITH RAC1 AND CDC42.
RX   PubMed=18325335; DOI=10.1016/j.febslet.2008.01.064;
RA   Matsuda C., Kameyama K., Suzuki A., Mishima W., Yamaji S., Okamoto H.,
RA   Nishino I., Hayashi Y.K.;
RT   "Affixin activates Rac1 via betaPIX in C2C12 myoblast.";
RL   FEBS Lett. 582:1189-1196(2008).
RN   [29]
RP   INTERACTION WITH SCRIB.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N., Etienne-Manneville S.,
RA   Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-204; THR-212; THR-219;
RP   SER-220 AND THR-230, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144; SER-149; SER-174;
RP   SER-223 AND THR-230, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-212.
RX   PubMed=23260667; DOI=10.1016/j.celrep.2012.11.018;
RA   Li D.Q., Nair S.S., Ohshiro K., Kumar A., Nair V.S., Pakala S.B.,
RA   Reddy S.D., Gajula R.P., Eswaran J., Aravind L., Kumar R.;
RT   "MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled
RT   chromatin remodeling during the DNA damage response.";
RL   Cell Rep. 2:1657-1669(2012).
RN   [36]
RP   FUNCTION, INTERACTION WITH BRSK2, AND PHOSPHORYLATION AT THR-423.
RX   PubMed=22669945; DOI=10.1074/jbc.m112.378372;
RA   Nie J., Sun C., Faruque O., Ye G., Li J., Liang Q., Chang Z., Yang W.,
RA   Han X., Shi Y.;
RT   "Synapses of amphids defective (SAD-A) kinase promotes glucose-stimulated
RT   insulin secretion through activation of p21-activated kinase (PAK1) in
RT   pancreatic beta-Cells.";
RL   J. Biol. Chem. 287:26435-26444(2012).
RN   [37]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   INTERACTION WITH CIB1 ISOFORM 2.
RC   TISSUE=Brain;
RX   PubMed=23503467; DOI=10.1038/onc.2013.43;
RA   Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V.,
RA   Vandoninck S., Van Lint J., Illing A., Seufferlein T.;
RT   "A novel splice variant of calcium and integrin-binding protein 1 mediates
RT   protein kinase D2-stimulated tumour growth by regulating angiogenesis.";
RL   Oncogene 33:1167-1180(2014).
RN   [41]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=23633677; DOI=10.1126/scisignal.2003627;
RA   Borroni E.M., Cancellieri C., Vacchini A., Benureau Y., Lagane B.,
RA   Bachelerie F., Arenzana-Seisdedos F., Mizuno K., Mantovani A., Bonecchi R.,
RA   Locati M.;
RT   "Beta-arrestin-dependent activation of the cofilin pathway is required for
RT   the scavenging activity of the atypical chemokine receptor D6.";
RL   Sci. Signal. 6:RA30-RA30(2013).
RN   [42]
RP   FUNCTION, COLOCALIZATION WITH RUFY3, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=25766321; DOI=10.1038/cddis.2015.50;
RA   Wang G., Zhang Q., Song Y., Wang X., Guo Q., Zhang J., Li J., Han Y.,
RA   Miao Z., Li F.;
RT   "PAK1 regulates RUFY3-mediated gastric cancer cell migration and
RT   invasion.";
RL   Cell Death Dis. 6:E1682-E1682(2015).
RN   [43]
RP   FUNCTION, INTERACTION WITH ARHGEF7; GAMMA-TUBULIN AND GIT1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27012601; DOI=10.1016/j.bbamcr.2016.03.016;
RA   Cernohorska M., Sulimenko V., Hajkova Z., Sulimenko T., Sladkova V.,
RA   Vinopal S., Draberova E., Draber P.;
RT   "GIT1/betaPIX signaling proteins and PAK1 kinase regulate microtubule
RT   nucleation.";
RL   Biochim. Biophys. Acta 1863:1282-1297(2016).
RN   [44]
RP   INTERACTION WITH INPP5K.
RX   PubMed=26940976; DOI=10.1111/gtc.12353;
RA   Ijuin T., Hatano N., Takenawa T.;
RT   "Glucose-regulated protein 78 (GRP78) binds directly to PIP3 phosphatase
RT   SKIP and determines its localization.";
RL   Genes Cells 21:457-465(2016).
RN   [45]
RP   INVOLVEMENT IN IDDMSSD, VARIANTS IDDMSSD CYS-131 AND CYS-429,
RP   CHARACTERIZATION OF VARIANTS IDDMSSD CYS-131 AND CYS-429, FUNCTION, AND
RP   HOMODIMERIZATION.
RX   PubMed=30290153; DOI=10.1016/j.ajhg.2018.09.005;
RA   Harms F.L., Kloth K., Bley A., Denecke J., Santer R., Lessel D., Hempel M.,
RA   Kutsche K.;
RT   "Activating mutations in PAK1, encoding p21-activated kinase 1, cause a
RT   neurodevelopmental disorder.";
RL   Am. J. Hum. Genet. 103:579-591(2018).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 70-545.
RX   PubMed=10975528; DOI=10.1016/s0092-8674(00)00043-x;
RA   Lei M., Lu W., Meng W., Parrini M.C., Eck M.J., Mayer B.J., Harrison S.C.;
RT   "Structure of PAK1 in an autoinhibited conformation reveals a multistage
RT   activation switch.";
RL   Cell 102:387-397(2000).
RN   [47]
RP   STRUCTURE BY NMR OF 183-204 IN COMPLEX WITH ARHGEF7, AND INTERACTION WITH
RP   ARHGEF7.
RX   PubMed=16101281; DOI=10.1021/bi050374a;
RA   Mott H.R., Nietlispach D., Evetts K.A., Owen D.;
RT   "Structural analysis of the SH3 domain of beta-PIX and its interaction with
RT   alpha-p21 activated kinase (PAK).";
RL   Biochemistry 44:10977-10983(2005).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 249-545, AND ACTIVITY REGULATION.
RX   PubMed=15893667; DOI=10.1016/j.str.2005.03.007;
RA   Lei M., Robinson M.A., Harrison S.C.;
RT   "The active conformation of the PAK1 kinase domain.";
RL   Structure 13:769-778(2005).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 248-545 OF MUTANT ARG-299 IN
RP   COMPLEX WITH ATP ANALOG AMP-PNP, MUTAGENESIS OF LYS-299; ASP-389 AND
RP   ASP-393, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBUNIT, AND
RP   PHOSPHORYLATION AT THR-423.
RX   PubMed=22153498; DOI=10.1016/j.str.2011.10.013;
RA   Wang J., Wu J.W., Wang Z.X.;
RT   "Structural insights into the autoactivation mechanism of p21-activated
RT   protein kinase.";
RL   Structure 19:1752-1761(2011).
CC   -!- FUNCTION: Protein kinase involved in intracellular signaling pathways
CC       downstream of integrins and receptor-type kinases that plays an
CC       important role in cytoskeleton dynamics, in cell adhesion, migration,
CC       proliferation, apoptosis, mitosis, and in vesicle-mediated transport
CC       processes (PubMed:11896197, PubMed:30290153). Can directly
CC       phosphorylate BAD and protects cells against apoptosis. Activated by
CC       interaction with CDC42 and RAC1. Functions as GTPase effector that
CC       links the Rho-related GTPases CDC42 and RAC1 to the JNK MAP kinase
CC       pathway. Phosphorylates and activates MAP2K1, and thereby mediates
CC       activation of downstream MAP kinases. Involved in the reorganization of
CC       the actin cytoskeleton, actin stress fibers and of focal adhesion
CC       complexes. Phosphorylates the tubulin chaperone TBCB and thereby plays
CC       a role in the regulation of microtubule biogenesis and organization of
CC       the tubulin cytoskeleton. Plays a role in the regulation of insulin
CC       secretion in response to elevated glucose levels. Part of a ternary
CC       complex that contains PAK1, DVL1 and MUSK that is important for MUSK-
CC       dependent regulation of AChR clustering during the formation of the
CC       neuromuscular junction (NMJ). Activity is inhibited in cells undergoing
CC       apoptosis, potentially due to binding of CDC2L1 and CDC2L2.
CC       Phosphorylates MYL9/MLC2. Phosphorylates RAF1 at 'Ser-338' and 'Ser-
CC       339' resulting in: activation of RAF1, stimulation of RAF1
CC       translocation to mitochondria, phosphorylation of BAD by RAF1, and RAF1
CC       binding to BCL2. Phosphorylates SNAI1 at 'Ser-246' promoting its
CC       transcriptional repressor activity by increasing its accumulation in
CC       the nucleus. In podocytes, promotes NR3C2 nuclear localization.
CC       Required for atypical chemokine receptor ACKR2-induced phosphorylation
CC       of LIMK1 and cofilin (CFL1) and for the up-regulation of ACKR2 from
CC       endosomal compartment to cell membrane, increasing its efficiency in
CC       chemokine uptake and degradation. In synapses, seems to mediate the
CC       regulation of F-actin cluster formation performed by SHANK3, maybe
CC       through CFL1 phosphorylation and inactivation. Plays a role in RUFY3-
CC       mediated facilitating gastric cancer cells migration and invasion
CC       (PubMed:25766321). In response to DNA damage, phosphorylates MORC2
CC       which activates its ATPase activity and facilitates chromatin
CC       remodeling (PubMed:23260667). In neurons, plays a crucial role in
CC       regulating GABA(A) receptor synaptic stability and hence GABAergic
CC       inhibitory synaptic transmission through its role in F-actin
CC       stabilization (By similarity). In hippocampal neurons, necessary for
CC       the formation of dendritic spines and excitatory synapses; this
CC       function is dependent on kinase activity and may be exerted by the
CC       regulation of actomyosin contractility through the phosphorylation of
CC       myosin II regulatory light chain (MLC) (By similarity). Along with
CC       GIT1, positively regulates microtubule nucleation during interphase
CC       (PubMed:27012601). {ECO:0000250|UniProtKB:O88643,
CC       ECO:0000250|UniProtKB:P35465, ECO:0000269|PubMed:10551809,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11896197,
CC       ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:12876277,
CC       ECO:0000269|PubMed:14585966, ECO:0000269|PubMed:15611088,
CC       ECO:0000269|PubMed:15831477, ECO:0000269|PubMed:15833848,
CC       ECO:0000269|PubMed:17726028, ECO:0000269|PubMed:17989089,
CC       ECO:0000269|PubMed:22669945, ECO:0000269|PubMed:23260667,
CC       ECO:0000269|PubMed:23633677, ECO:0000269|PubMed:25766321,
CC       ECO:0000269|PubMed:27012601, ECO:0000269|PubMed:30290153,
CC       ECO:0000269|PubMed:8805275, ECO:0000269|PubMed:9032240,
CC       ECO:0000269|PubMed:9395435, ECO:0000269|PubMed:9528787}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:22153498,
CC         ECO:0000269|PubMed:9032240};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10551809,
CC         ECO:0000269|PubMed:22153498, ECO:0000269|PubMed:9032240};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by binding small G proteins. Binding of
CC       GTP-bound CDC42 or RAC1 to the autoregulatory region releases monomers
CC       from the autoinhibited dimer, and enables activation by phosphorylation
CC       of Thr-423 (PubMed:10995762, PubMed:11804587, PubMed:15893667,
CC       PubMed:9032240). Phosphorylation of Thr-84 by OXSR1 inhibits activation
CC       (By similarity). {ECO:0000250|UniProtKB:P35465,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:11804587,
CC       ECO:0000269|PubMed:15893667, ECO:0000269|PubMed:9032240}.
CC   -!- SUBUNIT: Homodimer; homodimerization results in autoinhibition
CC       (PubMed:30290153). Active as monomer. Interacts with GIT1
CC       (PubMed:27012601). Component of cytoplasmic complexes, which also
CC       contains PXN, ARHGEF7 and GIT1. Interacts with NISCH (By similarity).
CC       Interacts with DVL1; mediates the formation of a DVL1, MUSK and PAK1
CC       ternary complex involved in AChR clustering (By similarity). Binds to
CC       the caspase-cleaved p110 isoform of CDC2L1 and CDC2L2, p110C, but not
CC       the full-length proteins (PubMed:12624090). Interacts with ARHGEF7
CC       (PubMed:27012601, PubMed:16101281). Interacts tightly with GTP-bound
CC       but not GDP-bound CDC42/P21 and RAC1 (By similarity). Interacts with
CC       SCRIB (PubMed:18716323). Interacts with PDPK1 (PubMed:10995762).
CC       Interacts (via kinase domain) with RAF1 (PubMed:11733498). Interacts
CC       with NCK1 and NCK2 (PubMed:10026169). Interacts with TBCB
CC       (PubMed:15831477). Interacts with BRSK2 (By similarity). Interacts with
CC       SNAI1 (PubMed:15833848). Interacts with CIB1 isoform 2
CC       (PubMed:23503467). Interacts with CIB1 (via N-terminal region); the
CC       interaction is direct, promotes PAK1 activity and occurs in a calcium-
CC       dependent manner. Interacts with INPP5K (PubMed:26940976). Interacts
CC       with gamma-tubulin (PubMed:27012601). {ECO:0000250|UniProtKB:O88643,
CC       ECO:0000250|UniProtKB:P35465, ECO:0000269|PubMed:10026169,
CC       ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:10995762,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11804587,
CC       ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:14585966,
CC       ECO:0000269|PubMed:15831477, ECO:0000269|PubMed:15833848,
CC       ECO:0000269|PubMed:16061695, ECO:0000269|PubMed:16101281,
CC       ECO:0000269|PubMed:16278681, ECO:0000269|PubMed:18325335,
CC       ECO:0000269|PubMed:18716323, ECO:0000269|PubMed:22153498,
CC       ECO:0000269|PubMed:22669945, ECO:0000269|PubMed:23503467,
CC       ECO:0000269|PubMed:26940976, ECO:0000269|PubMed:27012601,
CC       ECO:0000269|PubMed:30290153}.
CC   -!- INTERACTION:
CC       Q13153; P11117: ACP2; NbExp=3; IntAct=EBI-1307, EBI-2907070;
CC       Q13153; P35611: ADD1; NbExp=3; IntAct=EBI-1307, EBI-2809187;
CC       Q13153; Q15052: ARHGEF6; NbExp=4; IntAct=EBI-1307, EBI-1642523;
CC       Q13153; Q14155: ARHGEF7; NbExp=12; IntAct=EBI-1307, EBI-717515;
CC       Q13153; Q9H0W9-3: C11orf54; NbExp=3; IntAct=EBI-1307, EBI-12108466;
CC       Q13153; P60953: CDC42; NbExp=12; IntAct=EBI-1307, EBI-81752;
CC       Q13153; P21127: CDK11B; NbExp=4; IntAct=EBI-1307, EBI-1298;
CC       Q13153; Q8N1N5: CRIPAK; NbExp=6; IntAct=EBI-1307, EBI-1205846;
CC       Q13153; P63167: DYNLL1; NbExp=4; IntAct=EBI-1307, EBI-349105;
CC       Q13153; Q6NZ36-4: FAAP20; NbExp=3; IntAct=EBI-1307, EBI-12013806;
CC       Q13153; Q9Y2X7: GIT1; NbExp=5; IntAct=EBI-1307, EBI-466061;
CC       Q13153; Q14161: GIT2; NbExp=3; IntAct=EBI-1307, EBI-1046878;
CC       Q13153; Q13322-4: GRB10; NbExp=3; IntAct=EBI-1307, EBI-12353035;
CC       Q13153; Q14145: KEAP1; NbExp=5; IntAct=EBI-1307, EBI-751001;
CC       Q13153; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-1307, EBI-714379;
CC       Q13153; Q14847-2: LASP1; NbExp=3; IntAct=EBI-1307, EBI-9088686;
CC       Q13153; P53667: LIMK1; NbExp=5; IntAct=EBI-1307, EBI-444403;
CC       Q13153; Q15759: MAPK11; NbExp=3; IntAct=EBI-1307, EBI-298304;
CC       Q13153; O43639: NCK2; NbExp=10; IntAct=EBI-1307, EBI-713635;
CC       Q13153; Q9Y239: NOD1; NbExp=3; IntAct=EBI-1307, EBI-1051262;
CC       Q13153; P32243-2: OTX2; NbExp=3; IntAct=EBI-1307, EBI-9087860;
CC       Q13153; Q15365: PCBP1; NbExp=2; IntAct=EBI-1307, EBI-946095;
CC       Q13153; Q8N490-3: PNKD; NbExp=3; IntAct=EBI-1307, EBI-25879276;
CC       Q13153; P63000: RAC1; NbExp=25; IntAct=EBI-1307, EBI-413628;
CC       Q13153; P63000-1: RAC1; NbExp=3; IntAct=EBI-1307, EBI-7212896;
CC       Q13153; Q8WZ73-3: RFFL; NbExp=3; IntAct=EBI-1307, EBI-25839575;
CC       Q13153; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-1307, EBI-6285694;
CC       Q13153; Q92963: RIT1; NbExp=4; IntAct=EBI-1307, EBI-365845;
CC       Q13153; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-1307, EBI-9089805;
CC       Q13153; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-1307, EBI-2659201;
CC       Q13153; O75558: STX11; NbExp=3; IntAct=EBI-1307, EBI-714135;
CC       Q13153; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-1307, EBI-11123832;
CC       Q13153; O15273: TCAP; NbExp=3; IntAct=EBI-1307, EBI-954089;
CC       Q13153; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-1307, EBI-3923210;
CC       Q13153; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-1307, EBI-12090309;
CC       Q13153; O60830: TIMM17B; NbExp=3; IntAct=EBI-1307, EBI-2372529;
CC       Q13153; Q96A04: TSACC; NbExp=3; IntAct=EBI-1307, EBI-740411;
CC       Q13153; Q9H892-2: TTC12; NbExp=3; IntAct=EBI-1307, EBI-10274410;
CC       Q13153; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-1307, EBI-25830993;
CC       Q13153; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1307, EBI-12010736;
CC       Q13153; P60766: Cdc42; Xeno; NbExp=3; IntAct=EBI-1307, EBI-81763;
CC       Q13153; P63001: Rac1; Xeno; NbExp=3; IntAct=EBI-1307, EBI-413646;
CC       Q13153; Q5PP90: US3(L); Xeno; NbExp=2; IntAct=EBI-1307, EBI-15780451;
CC       Q13153-1; Q13153-1: PAK1; NbExp=2; IntAct=EBI-15628682, EBI-15628682;
CC       Q13153-1; Q15365: PCBP1; NbExp=5; IntAct=EBI-15628682, EBI-946095;
CC       Q13153-2; Q7L0Q8: RHOU; NbExp=2; IntAct=EBI-1019502, EBI-1638043;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11896197,
CC       ECO:0000269|PubMed:23260667, ECO:0000269|PubMed:25766321}. Cell
CC       junction, focal adhesion {ECO:0000269|PubMed:11896197,
CC       ECO:0000269|PubMed:25766321}. Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:11896197}. Cell membrane
CC       {ECO:0000269|PubMed:25766321}. Cell projection, ruffle membrane
CC       {ECO:0000269|PubMed:25766321}. Cell projection, invadopodium
CC       {ECO:0000269|PubMed:25766321}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:23260667}. Chromosome
CC       {ECO:0000269|PubMed:23260667}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:27012601}.
CC       Note=Colocalizes with RUFY3, F-actin and other core migration
CC       components in invadopodia at the cell periphery (PubMed:25766321).
CC       Recruited to the cell membrane by interaction with CDC42 and RAC1.
CC       Recruited to focal adhesions upon activation. Colocalized with CIB1
CC       within membrane ruffles during cell spreading upon readhesion to
CC       fibronectin. Upon DNA damage, translocates to the nucleoplasm when
CC       phosphorylated at Thr-212 where is co-recruited with MORC2 on damaged
CC       chromatin (PubMed:23260667). Localization to the centrosome does not
CC       depend upon the presence of gamma-tubulin (PubMed:27012601).
CC       Localization of the active, but not inactive, protein to the adhesions
CC       and edge of lamellipodia is mediated by interaction with GIT1
CC       (PubMed:11896197). {ECO:0000250|UniProtKB:P35465,
CC       ECO:0000269|PubMed:11896197, ECO:0000269|PubMed:23260667,
CC       ECO:0000269|PubMed:25766321, ECO:0000269|PubMed:27012601}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13153-1; Sequence=Displayed;
CC       Name=2; Synonyms=PAK1B;
CC         IsoId=Q13153-2; Sequence=VSP_017507;
CC   -!- TISSUE SPECIFICITY: Overexpressed in gastric cancer cells and tissues
CC       (at protein level) (PubMed:25766321). {ECO:0000269|PubMed:25766321}.
CC   -!- PTM: Autophosphorylated in trans, meaning that in a dimer, one kinase
CC       molecule phosphorylates the other one. Activated by autophosphorylation
CC       at Thr-423 in response to a conformation change, triggered by
CC       interaction with GTP-bound CDC42 or RAC1. Activated by phosphorylation
CC       at Thr-423 by BRSK2 and by PDPK1. Phosphorylated by JAK2 in response to
CC       PRL; this increases PAK1 kinase activity. Phosphorylated at Ser-21 by
CC       PKB/AKT; this reduces interaction with NCK1 and association with focal
CC       adhesion sites. Upon DNA damage, phosphorylated at Thr-212 and
CC       translocates to the nucleoplasm (PubMed:23260667). Phosphorylated at
CC       tyrosine residues, which can be enhanced by NTN1 (By similarity).
CC       {ECO:0000250|UniProtKB:O88643, ECO:0000269|PubMed:10551809,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:14585966,
CC       ECO:0000269|PubMed:17726028, ECO:0000269|PubMed:17989089,
CC       ECO:0000269|PubMed:22153498, ECO:0000269|PubMed:22669945,
CC       ECO:0000269|PubMed:23260667, ECO:0000269|PubMed:23633677}.
CC   -!- DISEASE: Intellectual developmental disorder with macrocephaly,
CC       seizures, and speech delay (IDDMSSD) [MIM:618158]: An autosomal
CC       dominant neurodevelopmental disorder characterized by impaired
CC       intellectual development, poor speech, postnatal macrocephaly, and
CC       seizures. {ECO:0000269|PubMed:30290153}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- CAUTION: The interaction between DSCAM, PAK1 and RAC1 has beend
CC       described. This article has been withdrawn by the authors.
CC       {ECO:0000305|PubMed:15169762, ECO:0000305|PubMed:26048998}.
CC   -!- CAUTION: There are data describing interaction and regulation by the
CC       product of CRIPAK, a putative single exon gene (PubMed:16278681).
CC       However, considering all available data there is no sufficient
CC       supporting evidence for the existence of such protein.
CC       {ECO:0000269|PubMed:16278681, ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAK1ID41633ch11q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U51120; AAC50590.1; -; mRNA.
DR   EMBL; U24152; AAA65441.1; -; mRNA.
DR   EMBL; AF071884; AAC24716.1; -; mRNA.
DR   EMBL; AP000486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109299; AAI09300.1; -; mRNA.
DR   CCDS; CCDS44687.1; -. [Q13153-2]
DR   CCDS; CCDS8250.1; -. [Q13153-1]
DR   PIR; G01773; G01773.
DR   RefSeq; NP_001122092.1; NM_001128620.1. [Q13153-2]
DR   RefSeq; NP_002567.3; NM_002576.4. [Q13153-1]
DR   RefSeq; XP_011543382.1; XM_011545080.2.
DR   RefSeq; XP_011543383.1; XM_011545081.2.
DR   RefSeq; XP_011543384.1; XM_011545082.2. [Q13153-2]
DR   RefSeq; XP_011543385.1; XM_011545083.2.
DR   RefSeq; XP_011543386.1; XM_011545084.2. [Q13153-2]
DR   RefSeq; XP_016873335.1; XM_017017846.1. [Q13153-1]
DR   RefSeq; XP_016873336.1; XM_017017847.1.
DR   RefSeq; XP_016873337.1; XM_017017848.1.
DR   RefSeq; XP_016873338.1; XM_017017849.1.
DR   RefSeq; XP_016873339.1; XM_017017850.1.
DR   PDB; 1F3M; X-ray; 2.30 A; A/B=70-149, C/D=249-545.
DR   PDB; 1YHV; X-ray; 1.80 A; A=249-545.
DR   PDB; 1YHW; X-ray; 1.80 A; A=249-545.
DR   PDB; 1ZSG; NMR; -; B=183-204.
DR   PDB; 2HY8; X-ray; 2.00 A; 1=249-545.
DR   PDB; 2QME; X-ray; 1.75 A; I=74-109.
DR   PDB; 3DVP; X-ray; 2.50 A; C/D=212-221.
DR   PDB; 3FXZ; X-ray; 1.64 A; A=249-545.
DR   PDB; 3FY0; X-ray; 2.35 A; A=249-545.
DR   PDB; 3Q4Z; X-ray; 1.89 A; A/B=248-545.
DR   PDB; 3Q52; X-ray; 1.80 A; A=248-545.
DR   PDB; 3Q53; X-ray; 2.09 A; A=248-545.
DR   PDB; 4DAW; X-ray; 2.00 A; A=249-545.
DR   PDB; 4EQC; X-ray; 2.01 A; A=249-545.
DR   PDB; 4O0R; X-ray; 2.40 A; A/B=249-545.
DR   PDB; 4O0T; X-ray; 2.60 A; A/B=249-545.
DR   PDB; 4P90; X-ray; 2.49 A; A/B=249-545.
DR   PDB; 4ZJI; X-ray; 1.99 A; A/B/C/D=249-545.
DR   PDB; 4ZJJ; X-ray; 2.20 A; A/B/C/D=249-545.
DR   PDB; 4ZLO; X-ray; 2.50 A; A/B=249-545.
DR   PDB; 4ZY4; X-ray; 2.60 A; A/B=249-545.
DR   PDB; 4ZY5; X-ray; 2.35 A; A/B=249-545.
DR   PDB; 4ZY6; X-ray; 2.15 A; A/B=249-545.
DR   PDB; 5DEW; X-ray; 1.90 A; A/B=249-545.
DR   PDB; 5DEY; X-ray; 2.10 A; A/B=249-545.
DR   PDB; 5DFP; X-ray; 2.20 A; A=249-545.
DR   PDB; 5IME; X-ray; 2.22 A; A/B=249-545.
DR   PDB; 5KBQ; X-ray; 2.58 A; A/B=254-542.
DR   PDB; 5KBR; X-ray; 2.36 A; A/B=254-542.
DR   PDB; 6B16; X-ray; 2.29 A; A/B=249-545.
DR   PDBsum; 1F3M; -.
DR   PDBsum; 1YHV; -.
DR   PDBsum; 1YHW; -.
DR   PDBsum; 1ZSG; -.
DR   PDBsum; 2HY8; -.
DR   PDBsum; 2QME; -.
DR   PDBsum; 3DVP; -.
DR   PDBsum; 3FXZ; -.
DR   PDBsum; 3FY0; -.
DR   PDBsum; 3Q4Z; -.
DR   PDBsum; 3Q52; -.
DR   PDBsum; 3Q53; -.
DR   PDBsum; 4DAW; -.
DR   PDBsum; 4EQC; -.
DR   PDBsum; 4O0R; -.
DR   PDBsum; 4O0T; -.
DR   PDBsum; 4P90; -.
DR   PDBsum; 4ZJI; -.
DR   PDBsum; 4ZJJ; -.
DR   PDBsum; 4ZLO; -.
DR   PDBsum; 4ZY4; -.
DR   PDBsum; 4ZY5; -.
DR   PDBsum; 4ZY6; -.
DR   PDBsum; 5DEW; -.
DR   PDBsum; 5DEY; -.
DR   PDBsum; 5DFP; -.
DR   PDBsum; 5IME; -.
DR   PDBsum; 5KBQ; -.
DR   PDBsum; 5KBR; -.
DR   PDBsum; 6B16; -.
DR   AlphaFoldDB; Q13153; -.
DR   BMRB; Q13153; -.
DR   SMR; Q13153; -.
DR   BioGRID; 111095; 186.
DR   CORUM; Q13153; -.
DR   DIP; DIP-31016N; -.
DR   ELM; Q13153; -.
DR   IntAct; Q13153; 172.
DR   MINT; Q13153; -.
DR   STRING; 9606.ENSP00000278568; -.
DR   BindingDB; Q13153; -.
DR   ChEMBL; CHEMBL4600; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13153; -.
DR   GuidetoPHARMACOLOGY; 2133; -.
DR   MoonDB; Q13153; Predicted.
DR   GlyGen; Q13153; 1 site.
DR   iPTMnet; Q13153; -.
DR   MetOSite; Q13153; -.
DR   PhosphoSitePlus; Q13153; -.
DR   BioMuta; PAK1; -.
DR   DMDM; 90111767; -.
DR   EPD; Q13153; -.
DR   jPOST; Q13153; -.
DR   MassIVE; Q13153; -.
DR   MaxQB; Q13153; -.
DR   PaxDb; Q13153; -.
DR   PeptideAtlas; Q13153; -.
DR   PRIDE; Q13153; -.
DR   ProteomicsDB; 59193; -. [Q13153-1]
DR   ProteomicsDB; 59194; -. [Q13153-2]
DR   Antibodypedia; 1132; 1429 antibodies from 49 providers.
DR   DNASU; 5058; -.
DR   Ensembl; ENST00000278568.8; ENSP00000278568.4; ENSG00000149269.10. [Q13153-2]
DR   Ensembl; ENST00000356341.8; ENSP00000348696.4; ENSG00000149269.10. [Q13153-1]
DR   GeneID; 5058; -.
DR   KEGG; hsa:5058; -.
DR   MANE-Select; ENST00000356341.8; ENSP00000348696.4; NM_002576.5; NP_002567.3.
DR   UCSC; uc001oyg.5; human. [Q13153-1]
DR   CTD; 5058; -.
DR   DisGeNET; 5058; -.
DR   GeneCards; PAK1; -.
DR   HGNC; HGNC:8590; PAK1.
DR   HPA; ENSG00000149269; Low tissue specificity.
DR   MalaCards; PAK1; -.
DR   MIM; 602590; gene.
DR   MIM; 618158; phenotype.
DR   neXtProt; NX_Q13153; -.
DR   OpenTargets; ENSG00000149269; -.
DR   PharmGKB; PA32917; -.
DR   VEuPathDB; HostDB:ENSG00000149269; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00950000182988; -.
DR   InParanoid; Q13153; -.
DR   OMA; IEISTPY; -.
DR   OrthoDB; 757766at2759; -.
DR   PhylomeDB; Q13153; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q13153; -.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-445355; Smooth Muscle Contraction.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-8964616; G beta:gamma signalling through CDC42.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   SignaLink; Q13153; -.
DR   SIGNOR; Q13153; -.
DR   BioGRID-ORCS; 5058; 21 hits in 1110 CRISPR screens.
DR   ChiTaRS; PAK1; human.
DR   EvolutionaryTrace; Q13153; -.
DR   GeneWiki; PAK1; -.
DR   GenomeRNAi; 5058; -.
DR   Pharos; Q13153; Tchem.
DR   PRO; PR:Q13153; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q13153; protein.
DR   Bgee; ENSG00000149269; Expressed in middle temporal gyrus and 179 other tissues.
DR   ExpressionAtlas; Q13153; baseline and differential.
DR   Genevisible; Q13153; HS.
DR   GO; GO:0005884; C:actin filament; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0014704; C:intercalated disc; ISS:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0031965; C:nuclear membrane; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030018; C:Z disc; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IPI:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt.
DR   GO; GO:0140678; F:molecular function inhibitor activity; IDA:DisProt.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006887; P:exocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; IMP:CAFA.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0051179; P:localization; IDA:DisProt.
DR   GO; GO:0060244; P:negative regulation of cell proliferation involved in contact inhibition; IMP:UniProtKB.
DR   GO; GO:0048812; P:neuron projection morphogenesis; ISS:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0090063; P:positive regulation of microtubule nucleation; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:CAFA.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0050770; P:regulation of axonogenesis; IBA:GO_Central.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IMP:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   IDEAL; IID00277; -.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   Apoptosis; ATP-binding; Cell junction; Cell membrane; Cell projection;
KW   Chromosome; Cytoplasm; Cytoskeleton; Disease variant; Epilepsy; Exocytosis;
KW   Intellectual disability; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..545
FT                   /note="Serine/threonine-protein kinase PAK 1"
FT                   /id="PRO_0000086460"
FT   DOMAIN          75..88
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          270..521
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..77
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          70..140
FT                   /note="Autoregulatory region"
FT   REGION          75..105
FT                   /note="GTPase-binding"
FT   REGION          159..198
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          211..251
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        42..77
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        216..236
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        237..251
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        389
FT                   /note="Proton acceptor"
FT   BINDING         276..284
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         299
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         345..347
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         21
FT                   /note="Phosphoserine; by PKB and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14585966,
FT                   ECO:0000269|PubMed:17989089"
FT   MOD_RES         57
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17989089"
FT   MOD_RES         84
FT                   /note="Phosphothreonine; by OXSR1"
FT                   /evidence="ECO:0000250|UniProtKB:P35465"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         131
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17989089"
FT   MOD_RES         142
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17989089"
FT   MOD_RES         144
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         149
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         153
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000269|PubMed:17726028,
FT                   ECO:0000269|PubMed:17989089"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17989089,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         185
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17989089"
FT   MOD_RES         199
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P35465"
FT   MOD_RES         201
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000269|PubMed:17726028"
FT   MOD_RES         204
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         212
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17989089,
FT                   ECO:0000269|PubMed:23260667, ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         219
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         220
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         223
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         225
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O88643"
FT   MOD_RES         229
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O88643"
FT   MOD_RES         230
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         285
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000269|PubMed:17726028,
FT                   ECO:0000269|PubMed:17989089"
FT   MOD_RES         423
FT                   /note="Phosphothreonine; by autocatalysis, BRSK2 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:10551809,
FT                   ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:22153498,
FT                   ECO:0000269|PubMed:22669945"
FT   VAR_SEQ         518..545
FT                   /note="HQFLKIAKPLSSLTPLIAAAKEATKNNH -> VRKLRFQVFSNFSMIAASIP
FT                   EDCQAPLQPHSTDCCS (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_017507"
FT   VARIANT         131
FT                   /note="Y -> C (in IDDMSSD; gain of function; enhanced PAK1
FT                   kinase activity and significantly reduced homodimerization;
FT                   dbSNP:rs1565638316)"
FT                   /evidence="ECO:0000269|PubMed:30290153"
FT                   /id="VAR_081554"
FT   VARIANT         429
FT                   /note="Y -> C (in IDDMSSD; gain-of-function; enhanced PAK1
FT                   kinase activity and significantly reduced homodimerization;
FT                   dbSNP:rs1565583382)"
FT                   /evidence="ECO:0000269|PubMed:30290153"
FT                   /id="VAR_081555"
FT   VARIANT         515
FT                   /note="L -> V (in dbSNP:rs35345144)"
FT                   /id="VAR_051654"
FT   MUTAGEN         83
FT                   /note="H->L: Abolishes interaction with CDC42, leading to
FT                   strongly decreased activity; when associated with L-86."
FT                   /evidence="ECO:0000269|PubMed:10551809,
FT                   ECO:0000269|PubMed:9774440"
FT   MUTAGEN         86
FT                   /note="H->L: Abolishes interaction with CDC42, leading to
FT                   strongly decreased activity; when associated with L-83."
FT                   /evidence="ECO:0000269|PubMed:10551809,
FT                   ECO:0000269|PubMed:9774440"
FT   MUTAGEN         107
FT                   /note="L->F: Abolishes autoinhibition, leading to
FT                   constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10551809"
FT   MUTAGEN         299
FT                   /note="K->R: Strongly decreases activity. Abolishes kinase
FT                   activity; when associated with N-389."
FT                   /evidence="ECO:0000269|PubMed:22153498"
FT   MUTAGEN         389
FT                   /note="D->N: Abolishes kinase activity; when associated
FT                   with R-299."
FT                   /evidence="ECO:0000269|PubMed:22153498"
FT   MUTAGEN         393
FT                   /note="D->A: Abolishes autophosphorylation at Thr-423."
FT                   /evidence="ECO:0000269|PubMed:22153498"
FT   MUTAGEN         423
FT                   /note="T->A: Decreases CDC42-stimulated activity and
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10551809"
FT   MUTAGEN         423
FT                   /note="T->E: Constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10551809"
FT   CONFLICT        26
FT                   /note="A -> V (in Ref. 2; AAA65441 and 3; AAC24716)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        237
FT                   /note="R -> L (in Ref. 1; AAC50590)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        379
FT                   /note="F -> S (in Ref. 1; AAC50590)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        503
FT                   /note="E -> D (in Ref. 2; AAA65441)"
FT                   /evidence="ECO:0000305"
FT   STRAND          79..87
FT                   /evidence="ECO:0007829|PDB:2QME"
FT   TURN            91..94
FT                   /evidence="ECO:0007829|PDB:2QME"
FT   STRAND          95..98
FT                   /evidence="ECO:0007829|PDB:1F3M"
FT   HELIX           101..108
FT                   /evidence="ECO:0007829|PDB:1F3M"
FT   HELIX           114..119
FT                   /evidence="ECO:0007829|PDB:1F3M"
FT   HELIX           121..135
FT                   /evidence="ECO:0007829|PDB:1F3M"
FT   STRAND          195..198
FT                   /evidence="ECO:0007829|PDB:1ZSG"
FT   STRAND          214..219
FT                   /evidence="ECO:0007829|PDB:3DVP"
FT   HELIX           250..260
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           266..268
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          270..272
FT                   /evidence="ECO:0007829|PDB:3Q4Z"
FT   STRAND          274..279
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          282..289
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   TURN            290..292
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          295..302
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           303..305
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           309..321
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          330..336
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          339..345
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          349..351
FT                   /evidence="ECO:0007829|PDB:4ZJI"
FT   HELIX           352..358
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           363..382
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           392..394
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          395..397
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   STRAND          408..410
FT                   /evidence="ECO:0007829|PDB:1F3M"
FT   STRAND          416..418
FT                   /evidence="ECO:0007829|PDB:3Q52"
FT   HELIX           428..430
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           433..437
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           444..459
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   TURN            463..466
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           469..479
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           487..489
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           492..501
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   TURN            506..508
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           512..515
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           519..523
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           527..530
FT                   /evidence="ECO:0007829|PDB:3FXZ"
FT   HELIX           531..540
FT                   /evidence="ECO:0007829|PDB:3FXZ"
SQ   SEQUENCE   545 AA;  60647 MW;  1A95CD5F2195CD7B CRC64;
     MSNNGLDIQD KPPAPPMRNT STMIGAGSKD AGTLNHGSKP LPPNPEEKKK KDRFYRSILP
     GDKTNKKKEK ERPEISLPSD FEHTIHVGFD AVTGEFTGMP EQWARLLQTS NITKSEQKKN
     PQAVLDVLEF YNSKKTSNSQ KYMSFTDKSA EDYNSSNALN VKAVSETPAV PPVSEDEDDD
     DDDATPPPVI APRPEHTKSV YTRSVIEPLP VTPTRDVATS PISPTENNTT PPDALTRNTE
     KQKKKPKMSD EEILEKLRSI VSVGDPKKKY TRFEKIGQGA SGTVYTAMDV ATGQEVAIKQ
     MNLQQQPKKE LIINEILVMR ENKNPNIVNY LDSYLVGDEL WVVMEYLAGG SLTDVVTETC
     MDEGQIAAVC RECLQALEFL HSNQVIHRDI KSDNILLGMD GSVKLTDFGF CAQITPEQSK
     RSTMVGTPYW MAPEVVTRKA YGPKVDIWSL GIMAIEMIEG EPPYLNENPL RALYLIATNG
     TPELQNPEKL SAIFRDFLNR CLEMDVEKRG SAKELLQHQF LKIAKPLSSL TPLIAAAKEA
     TKNNH
//
